All Title Author
Keywords Abstract

PLOS ONE  2009 

Quality of Pharmaceutical Advertisements in Medical Journals: A Systematic Review

DOI: 10.1371/journal.pone.0006350

Full-Text   Cite this paper   Add to My Lib


Background Journal advertising is one of the main sources of medicines information to doctors. Despite the availability of regulations and controls of drug promotion worldwide, information on medicines provided in journal advertising has been criticized in several studies for being of poor quality. However, no attempt has been made to systematically summarise this body of research. We designed this systematic review to assess all studies that have examined the quality of pharmaceutical advertisements for prescription products in medical and pharmacy journals. Methods and Findings Studies were identified via searching electronic databases, web library, search engine and reviewing citations (1950 – February 2006). Only articles published in English and examined the quality of information included in pharmaceutical advertisements for prescription products in medical or pharmacy journals were included. For each eligible article, a researcher independently extracted the data on the study methodology and outcomes. The data were then reviewed by a second researcher. Any disagreements were resolved by consensus. The data were analysed descriptively. The final analysis included 24 articles. The studies reviewed advertisements from 26 countries. The number of journals surveyed in each study ranged from four to 24 journals. Several outcome measures were examined including references and claims provided in advertisements, availability of product information, adherence to codes or guidelines and presentation of risk results. The majority of studies employed a convenience-sampling method. Brand name, generic name and indications were usually provided. Journal articles were commonly cited to support pharmaceutical claims. Less than 67% of the claims were supported by a systematic review, a meta-analysis or a randomised control trial. Studies that assessed misleading claims had at least one advertisement with a misleading claim. Two studies found that less than 28% of claims were unambiguous clinical claims. Most advertisements with quantitative information provided risk results as relative risk reduction. Studies were conducted in 26 countries only and then the generalizability of the results is limited. Conclusions Evidence from this review indicates that low quality of journal advertising is a global issue. As information provided in journal advertising has the potential to change doctors' prescribing behaviour, ongoing efforts to increase education about drug promotion are crucial. The results from our review suggest the need for a global pro-active and effective


[1]  (2000) Liebman M. Listen up, publishers say - journal advertising sells! Medical Marketing & Media 35(3): 89–94.
[2]  McGettigan P, Golden J, Fryer J, Chan R, Feely J (2001) Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message. British Journal of Clinical Pharmacology 51: 184–189.
[3]  Rohra DK, Gilani AH, Memon IK, Perven G, Khan MT, et al. (2006) Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. Journal of Pharmacy and Pharmaceutical Sciences 9: 50–59.
[4]  The Association of Medical Media. The case for medical journal advertising.
[5]  Prosser H, Almond S, Walley T (2003) Influences on GPs' decision to prescribe new drugs - the importance of who says what. Family Practice 20: 61–68.
[6]  World Health Organization. Ethical criteria for medical drug promotion.
[7]  International Federation of Pharmaceutical Manufacturers Associations(IFPMA). Code of Pharmaceutical Marketing.
[8]  Morris LA, Pines WL (2000) Regulation of pharmaceutical promotion in the twenty-first century. Drug Information Journal 34: 861–873.
[9]  The Organisation for Professionals in Regulatory Affairs. Worldwide survey on national controls of pharmaceutical advertising and promotion.
[10]  Carandang ED, Moulds RFW (1994) Pharmaceutical Advertisements in Australian Medical Publications - Have They Improved. Medical Journal of Australia 161:
[11]  Chirac P, Pikon A, Poinsignon Y, Vitry A (1993) Drug Marketing in French-Speaking African Countries. Social Science & Medicine 36: 1541–1543.
[12]  Cooper RJ, Schriger DL, Wallace RC, Mikulich VJ, Wilkes MS (2003) The quantity and quality of scientific graphs in pharmaceutical advertisements. Journal Of General Internal Medicine 18: 294–297.
[13]  Tomson G, Weerasuriya K (1990) Codes and Practice - Information in Drug Advertisements an Example from Sri-Lanka. Social Science & Medicine 31: 737–741.
[14]  Herxheimer A, Lundborg CS, Westerholm B (1993) Advertisements for Medicines in Leading Medical Journals in 18 Countries - a 12-Month Survey of Information-Content and Standards. International Journal of Health Services 23: 161–172.
[15]  Wilkes MS, Doblin BH, Shapiro MF (1992) Pharmaceutical Advertisements in Leading Medical Journals - Experts Assessments. Annals of Internal Medicine 116: 912–919.
[16]  de Carvalho Mastroianni P, Galduroz JCF, Carlini EA (2005) Psychoactive drug advertising: A comparison of technical information from three countries: Brazil, United States and United Kingdom. Sao Paulo Medical Journal 123: 209–214.
[17]  Lankinen KS, Levola T, Marttinen K, Puumalainen I, Helin-Salmivaara A (2004) Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals. Pharmacoepidemiology and Drug Safety 13: 789–795.
[18]  Lexchin J, Holbrook A (1994) Methodologic Quality and Relevance of References in Pharmaceutical Advertisements in a Canadian Medical Journal. Canadian Medical Association Journal 151: 47–54.
[19]  Cooper RJ, Schriger DL (2005) The availability of references and the sponsorship of original research cited in pharmaceutical advertisements. Canadian Medical Association Journal 172: 487–491.
[20]  Loke TW, Koh FC, Ward JE (2002) Pharmaceutical advertisement claims in Australian medical publications. Medical Journal of Australia 177: 291–293.
[21]  Gutknecht DR (2001) Evidence-based advertising? A survey of four major journals. J Am Board Fam Pract 14: 197–200.
[22]  Villanueva P, Peiro S, Librero J, Pereiro I (2003) Accuracy of pharmaceutical advertisements in medical journals. Lancet 361: 27–32.
[23]  Lal A (1998) Information contents of drug advertisements: An Indian experience. Annals of Pharmacotherapy 32: 1234–1238.
[24]  Lexchin J (1999) How patient outcomes are reported in drug advertisements - Review of Canadian medical journals. Canadian Family Physician 45: 1213–1216.
[25]  Hogan DJ, Sarel D, Canas A, Bellman B, Eaglstein W, et al. (1993) An Analysis of Advertisements in the Journal-of-the-American-Academy-of-Derma?tology,1980 and 1990. Journal of the American Academy of Dermatology 28: 993–997.
[26]  Moulds RFW, Bochner F, Wing LMH (1986) Drug Advertising. Medical Journal of Australia 145: 178–179.
[27]  Moulds RFW, Wing LMH (1989) Drug Advertising. Medical Journal of Australia 150: 410–411.
[28]  Moulds RFW, Day RO (1987) Drug Advertising. Medical Journal of Australia 147: 52.
[29]  Lal A, Moharana AK, Srivastava S (1997) Comparative evaluation of drug advertisements in Indian, British and American medical journals. Journal of the Indian Medical Association 95: 19–20.
[30]  Mastroianni PdC, Galduróz JCF, Carlini EA (2003) Influence of the legislation on the advertisement of psychoactive medications in Brazil. Revista Brasileira De Psiquiatria (S?o Paulo, Brazil: 1999) 25: 146–155.
[31]  Vlassov V, Mansfield P, Lexchin J, Vlassova A (2001) Do drug advertisements in Russian medical journals provide essential information for safe prescribing? Western Journal of Medicine 174: 391–394.
[32]  Cooper RJ, Schriger DL, Tashman DA (2001) An evaluation of the graphical literacy of Annals of Emergency Medicine. Annals of Emergency Medicine 37: 13–19.
[33]  Rothermich EA, Pathak DS, Smeenk DA (1996) Health-related quality-of-life claims in prescription drug advertisements. American Journal of Health-System Pharmacy 53: 1565–1569.
[34]  Stimson GV (1976) The use of references in drug advertisements. Journal of the Royal College of General Practitioners 26: Suppl 176–80.
[35]  Department of Essential Drugs and Medicine Policy. Drug Promotion Database.
[36]  Healthy skepticism.
[37]  Gilad J, Moran L, Schlaeffer F, Borer A (2005) Antibiotic drug advertising in medical journals. Scandinavian Journal of Infectious Diseases 37: 910–912.
[38]  Gitanjali B, Shashindran CH, Tripathi KD, Sethuraman KR (1997) Are drug advertisements in Indian edition of BMJ unethical? BMJ 315:
[39]  Lal A, Sharma ML (1992) Drug advertisements in Indian medical journals. Indian Journal Of Physiology And Pharmacology 36: 139–140.
[40]  Mindell J (1997) Evidence based advertising? Only two fifths of advertisements cited published, peer reviewed references. British Medical Journal 315: 1622–1622.
[41]  Smart S, Williams C (1997) Evidence based advertising - Half of drug advertisements in BMJ over six months cited no supporting evidence. British Medical Journal 315: 1622–1623.
[42]  Stimson GV (1975) Information contained in drug advertisements. British Medical Journal 4: 508–509.
[43]  Stalsby C, Westerholm B (1987) [Are drug advertisements of any informative value? Analysis of drug advertisements in the Swedish Medical Journal (Lakartidningen) and the Norwegian Medical Journal (Tidsskrift for Den norske laegeforening) during the first half of 1986]. Tidsskrift for Den Norske Laegeforening 107: 1573–1577.
[44]  Hansen FJ, Osborne D (1995) Portrayal of Women and Elderly Patients in Psychotropic-Drug Advertisements. Women & Therapy 16: 129–141.
[45]  Lovdahl U, Riska E (2000) The construction of gender and mental health in Nordic psychotropic-drug advertising. International Journal of Health Services 30: 387–406.
[46]  Munce SEPB, Robertson EKP, Sansom SNMA, Stewart DEMDFWho Is Portrayed in Psychotropic Drug Advertisements? [Article]: Journal of Nervous & Mental Disease April 2004; 192(4): 284–288.
[47]  Riska E, Hagglund U (1991) Advertising for Psychotropic-Drugs in the Nordic Countries - Metaphors, Gender and Life Situations. Social Science & Medicine 32: 465–471.
[48]  Smith MC, Griffin L (1977) Rationality of appeals used in the promotion of psychotropic drugs. A comparison of male and female models. Social Science & Medicine (1967) 11: 409–414.
[49]  Trigo Hervas MM, Garcia Lopez JA, Garcia Lopez MA (1995) Advertising of pharmaceutical products in professional pharmaceutical journals. Farmacia Clinica 12: 705–713.
[50]  Madridejos R, Cabezas C, Flor F (1996) Drug advertising in medical journals. Publicidad de medicamentos en las revistas me? dicas 17: 408–410.
[51]  Spigset O (1998) Are advertisements for pharmaceuticals reliable? [Kan man stole pa? legemiddelreklamen?]. Tidsskrift for den Norske Laegeforening 118: 4637–4641.
[52]  Sibanda N, Gavaza P, Maponga CC, Mugore L (2004) Pharmaceutical manufacturers' compliance with drug advertisement regulations in Zimbabwe. American Journal of Health-System Pharmacy 61:
[53]  Nelson CP, Bloom DA (2001) Sales and science: Changing patterns of pharmaceutical and medical device advertising in peer reviewed urology publications, 1975-2000. Journal of Urology 166: 2317–2320.
[54]  Tebbey P (2004) An exploratory content analysis of pharmaceutical ads in journals targetted to pediatricians. Marketing Management Journal 14: 138–152.
[55]  Brock TP, Smith MC (1998) Content analysis of the appeals used in advertising in the American Journal of Hospital Pharmacy in 1960, 1970, 1980, and 1990. Journal of Pharmaceutical Marketing & Management 12: 43–59.
[56]  Krupka LR, Vener AM (1985) Prescription Drug Advertising - Trends and Implications. Social Science & Medicine 20:
[57]  Rothermich EA, Pathak DS (1997) References for health-related quality-of-life claims in prescription drug advertisements. American Journal of Health-System Pharmacy 54: 2596–2599.
[58]  Ferber R (1966) Interpretation of Interest in Pharmaceutical Advertisements. Journal of Advertising Research 6: 8–13.
[59]  Lohiya S (2005) Pharmaceutical advertisements in medical journals received in a medical clinic: Are we having “too much of a good thing”? Journal of the National Medical Association 97: 718–720.
[60]  Stimson GV (1976) The extent of advertising of pharmaceutical products. Journal of the Royal College of General Practitioners 26: Suppl 169–76.
[61]  Jones M, Greenfield S, Bradley C (1999) A survey of the advertising of nine new drugs in the general practice literature. Journal of Clinical Pharmacy and Therapeutics 24:
[62]  Szeinbach SL, Juergens JP, Smith MC, Freeman RA (1991) Content analysis of pharmacoeconomic appeals in pharmaceutical drug product advertisements. Journal of Research in Pharmaceutical Economics 3: 75–90.
[63]  Wang TJ, Ausiello JC, Stafford RS (1999) Trends in antihypertensive drug advertising, 1985-1996. Circulation 99:
[64]  Roughead EE, Gilbert AL, Harvey KJ (1998) Self-regulatory codes of conduct: Are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners? International Journal of Health Services 28: 269–279.
[65]  Gottlieb S (1379) Congress criticises drugs industry for misleading advertising. Bmj 325: 14.
[66]  Mansfield PR, Lexchin J, Wen LS, Grandori L, McCoy CP, et al. (2006) Educating health professionals about drug and device promotion: advocates' recommendations.[see comment]. PLoS Medicine/Public Library of Science 3:
[67]  Nexoe J, Gyrd-Hansen D, Kragstrup J, Kristiansen IS, Nielsen JB (2002) Danish GPs' perception of disease risk and benefit of prevention. Family Practice 19: 3–6.
[68]  Ferry ME, Lamy PP, Becker LA (1985) Physicians' knowledge of prescribing for the elderly: A study of primary care physicians in Pennsylvania: Journal of the American Geriatrics Society. 33(9)(pp 616-625), 1985. Date of Publication 1985.
[69]  Becker MH, Stolley PD, Lasagna L, McEvilla JD, Sloane LM (1972) Differential education concerning therapeutics and resultant physician prescribing patterns. Journal of Medical Education 47: 118–127.
[70]  Bower AD, Burkett GL (1987) Family Physicians and Generic Drugs - a Study of Recognition, Information-Sources, Prescribing Attitudes, and Practices. Journal of Family Practice 24:
[71]  Dajda R (1978) Drug advertising and prescribing. Journal of the Royal College of General Practitioners 28: 538–541.
[72]  Avorn J, Chen M, Hartley R (1982) Scientific Versus Commercial Sources of Influence on the Prescribing Behavior of Physicians. American Journal of Medicine 73: 4–8.
[73]  Ziegler MG, Lew P, Singer BC (1995) The Accuracy of Drug Information from Pharmaceutical Sales Representatives. JAMA 273: 1296–1298.
[74]  Herxheimer A, Collier J (1990) Promotion by the British Pharmaceutical-Industry, 1983-8 - a Critical Analysis of Self Regulation. British Medical Journal 300: 307–311.
[75]  General Accounting Office. Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations.
[76]  Willet, L. Litigation as an Alternative to Regulation: Problems Created by Follow-On Lawsuits with Multiple Outcomes. The Georgetown Journal of Legal Ethics.
[77]  Fugh-Berman A, Alladin K, Chow J (2006) Advertising in medical journals: should current practices change? PLoS Medicine/Public Library of Science 3:
[78]  Jureidini J, Mansfield P (2003) The journal and drug advertising. Australian & New Zealand Journal of Psychiatry 37:
[79]  Wilkes MS, Kravitz RL (1995) Policies, practices, and attitudes of North American medical journal editors.[see comment]. Journal of General Internal Medicine 10: 443–450.
[80]  Public Library of Science. Support PLoS and Open Access.
[81]  Breckenridge AM (1986) The pharmaceutical industry and developing countries. British Journal of Clinical Pharmacology 22: Suppl 127S–29S.
[82]  Rohra DK, J A, Rehman T, Sukkurwala AQ, Palanpurwala AS, Gangwani R (2007) Prescription of new drugs by General Practitioners in Pakistan: An exploration into information sources, prescription influences and general attitudes. Pak J Med Res 2007; 46: 5–10.
[83]  Vancelik S, Beyhun NE, Acemoglu H, Calikoglu O, Vancelik S, et al. (2007) Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey. BMC Public Health 7: 122.
[84]  Wyeth. Wyeth Code of Conduct.
[85]  Norvatis. The Novartis Pharma Promotional Practices Policy.
[86]  Sweet M (2009) Pharmaceutical marketing and the internet Australian Prescriber 32:
[87]  Cegedim Dendrite. Direct-to-Consumer (DTC) Marketing for U.S. Prescription Drugs Moves.
[88]  Iskowitz M. Medical Marketing and Media: Pharma pursued safe haven for its CME spend last year.
[89]  What's wrong with CME? [editorial]. CMAJ 2004; 170 (6):


comments powered by Disqus